New evidence in hypertension and hyperlipidaemia

Heart

Volumn 90, Issue SUPPL. 4, 2004, Pages

  Chapman, N ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; PRAVASTATIN; SIMVASTATIN; ANGIOTENSIN RECEPTOR;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DRUG EFFECT; DRUG SCREENING; DRUG UTILIZATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; OUTCOMES RESEARCH; PATIENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; SENESCENCE; STROKE; DRUG ANTAGONISM; REVIEW;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CLINICAL TRIALS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; RECEPTORS, ANGIOTENSIN;

EID: 2442637571     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.037556     Document Type: Conference Paper

References (14)

1. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regiments on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
3. Dahlof B, Devereux RB, Kjeldsen SE, et al for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
4. Lithell H, Hansson L, Skoog I, et al for the SCOPE study group. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomised double-blind intervention trial. J Hypertens 2003;21:875-86.
5. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
6. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
8. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
9. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in eastern Asia. Lancet 1998;352:1801-7.
10. Zhang X, Patel A, Horibe H, et al for the Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003;32:563-72.
11. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
12. Shepherd J, Blauw GJ, Murphy MB, et al on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
13. Sever PS, Dahlof B, Poulter NR, et al for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial - lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
14. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.